Straits Times Index
3,301.96 +15.63 (+0.48%) S&P 500
4,229.20 +18.96 (+0.45%) Dow
33,483.47 +173.96 (+0.52%) Nasdaq
12,880.53 +25.72 (+0.20%) BTC-USD
24,459.25 +491.10 (+2.05%) CMC Crypto 200
578.01 +3.26 (+0.57%)
Organogenesis Holdings Inc. (ORGO)
- Motley Fool
Why Organogenesis Stock Is Tumbling Today
Shares of Organogenesis Holdings (NASDAQ: ORGO) fell by 19.6% as of 2:45 p.m. ET on Wednesday after the wound care company reported worse-than-anticipated Q2 earnings and also slashed its guidance for the rest of 2022. Its net revenue for the quarter was $121.4 million, a decline of 1% year over year, and its net income collapsed by 58% year over year to reach $8.7 million. For its fiscal 2022 earnings guidance, management now expects net revenue of between $465 million and $490 million, whereas in its initial guidance, it expected between $485 million and $515 million.
- Motley Fool
Organogenesis Holdings Inc. (ORGO) Q2 2022 Earnings Call Transcript
Good afternoon, ladies and gentlemen, and welcome to the second quarter 2022 earnings conference call for Organogenesis Holdings Inc. [Operator instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Let me start with a brief agenda of what we'll be covering during our prepared remarks.
- Zacks
Organogenesis (ORGO) Tops Q2 Earnings and Revenue Estimates
Organogenesis (ORGO) delivered earnings and revenue surprises of 12.50% and 0.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
